Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:02 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenosine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antecedent Metabolic Health and Metformin Aging Study

NCT04264897
View directory record Official record
Conditions
Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance
Interventions
Metformin, Placebo oral tablet
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
40 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Nov 3, 2026, 12:02 PM EST
Completed No phase listed Observational Results available

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

NCT01088503
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
ADP receptor inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
185
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Nov 3, 2026, 12:02 PM EST
Terminated Phase 2 Interventional Results available

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05177770
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
SRF617, etrumadenant, zimberelimab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Miami, Florida • Ann Arbor, Michigan • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 4 Interventional Results available

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

NCT03557385
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Iopamidol, adenosine, Navvus® Catheter, CVi® Contrast Delivery System
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Long Beach, California • Coon Rapids, Minnesota • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 3, 2026, 12:02 PM EST
Recruiting Phase 4 Interventional

Adenosine vs Diltiazem for Treatment of SVT in the ED

NCT06993038
View directory record Official record
Conditions
Supraventricular Tachycardia (SVT)
Interventions
adenosine, diltiazem
Drug
Lead sponsor
Anne E. Zepeski
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 1Phase 2 Interventional

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
Interventions
Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
17
States / cities
Cerritos, California • Encino, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 1 Interventional

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency

NCT00018018
View directory record Official record
Conditions
Severe Combined Immunodeficiency Syndrome
Interventions
CD34+ cells transduced with ADA retrovir
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Nov 3, 2026, 12:02 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

AMP as a Better Delivery System of Adenosine

NCT00179010
View directory record Official record
Conditions
Ischemia
Interventions
Adenosine, Adenosine Mono Phosphate (AMP)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Nov 3, 2026, 12:02 PM EST
Completed Not applicable Interventional Results available

AMPLATZER Duct Occluder II Additional Sizes

NCT03055858
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
ADO II AS (PDA closure)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
3 Days and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Orlando, Florida • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Nov 3, 2026, 12:02 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Role of Adenosine in the Release of VEGF and Cytokines

NCT00580905
View directory record Official record
Conditions
Inflammation
Interventions
Adenosine, Sodium Nitroprusside
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Nov 3, 2026, 12:02 PM EST
Recruiting Phase 2 Interventional

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NCT05408845
View directory record Official record
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
154
States / cities
Birmingham, Alabama • Duarte, California • Dublin, California + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 3 Interventional

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

NCT02565173
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Nov 3, 2026, 12:02 PM EST
Completed No phase listed Observational Results available

Registry Study of Revcovi Treatment in Patients With ADA-SCID

NCT03878069
View directory record Official record
Conditions
Adenosine Deaminase Severe Combined Immunodeficiency
Interventions
elapegademase-lvlr
Biological
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
0 Months to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Nov 3, 2026, 12:02 PM EST
Recruiting Early Phase 1 Interventional

Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

NCT07224269
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities
Interventions
Terazosine, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 12:02 PM EST
Terminated Phase 1 Interventional Results available

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

NCT04296942
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
Interventions
Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Nov 3, 2026, 12:02 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Cardiac Magnetic Resonance Imaging for Detecting Endothelial Dysfunction

NCT00808535
View directory record Official record
Conditions
Endothelial Dysfunction, Myocardial Perfusion Abnormalities, Cardiac MRI Perfusion With Vasomotor Stress, Diabetes
Interventions
Cardiac Perfusion MRI w Vasomotor Stress
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Nov 3, 2026, 12:02 PM EST
Completed No phase listed Observational

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study

NCT00001255
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 1 Interventional

Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

NCT00014248
View directory record Official record
Conditions
Cachexia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
adenosine triphosphate, quality-of-life assessment
Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 2 Interventional Results available

Clonidine Versus Adenosine to Treat Neuropathic Pain

NCT00349921
View directory record Official record
Conditions
Pain
Interventions
clonidine, adenosine, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Nov 3, 2026, 12:02 PM EST
Completed Phase 1Phase 2 Interventional Results available

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

NCT01852071
View directory record Official record
Conditions
ADA-SCID
Interventions
Infusion of autologous EFS-ADA LV CD34+ (OTL-101), busulfan, PEG-ADA ERT
Genetic · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 3, 2026, 12:02 PM EST
Completed Not applicable Interventional

Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?

NCT00205166
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cardiac SPECT imaging Rest and Stress, Caffeine
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Nov 3, 2026, 12:02 PM EST
Terminated Phase 1 Interventional Results available

First in Human Study of M1069 in Advanced Solid Tumors

NCT05198349
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
M1069
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Hackensack, New Jersey • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 3, 2026, 12:02 PM EST
Active, not recruiting Phase 2 Interventional Results available

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

NCT03587740
View directory record Official record
Conditions
Breast Cancer
Interventions
T-DM1
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
14
States / cities
Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 3, 2026, 12:02 PM EST